--- title: "Precision BioSciences prices $75,000,093 stock" url: "https://aibio.space/news/precision-biosciences-prices-75-000-093-stock-warrant-offering/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2025-11-12" section: "Financings" tickers: "NASDAQ:DTIL" source: "https://www.sec.gov/Archives/edgar/data/1357874/000162828025051369/pro-suppdraft1162025.htm" summary: "Guggenheim Securities, LLC is the sole underwriter. The company sells 10,815,000 shares, each with half a warrant, at a combined $6.14. Proceeds are $70,50" --- By the aibio.space news desk. Sources - [Precision BioSciences, Inc. 424B5 (2025-11-12)](https://www.sec.gov/Archives/edgar/data/1357874/000162828025051369/pro-suppdraft1162025.htm) - [Precision BioSciences, Inc. 10-K (2025-03-26): business](https://www.sec.gov/Archives/edgar/data/1357874/000095017025044775/dtil-20241231.htm) [DTIL](https://aibio.space/companies/precision-biosciences/) 2025-11-12 # Precision BioSciences prices $75,000,093 stock and warrant offering Tickers [DTIL](https://aibio.space/companies/precision-biosciences/) Guggenheim Securities, LLC is the sole underwriter. The company sells 10,815,000 shares, each with half a warrant, at a combined $6.14. Proceeds are $70,500,087 before expenses, and the as adjusted net tangible book value would be $3.74 a share. ## Key facts - **Company**: Precision BioSciences, Inc. (NASDAQ: DTIL) - **News type**: Financings - **Primary source**: [Precision BioSciences, Inc. 424B5 (2025-11-12)](https://www.sec.gov/Archives/edgar/data/1357874/000162828025051369/pro-suppdraft1162025.htm) *Midtown Manhattan and a downtown tower in haze. CC0, via rawpixel. The picture shows the field, not the companies named.* ## The terms Precision BioSciences, Inc. (Nasdaq: [DTIL](https://aibio.space/companies/precision-biosciences/)) priced an offering of 10,815,000 shares of common stock in a prospectus supplement dated November 10, 2025. Each share is sold together with one half of a warrant, so the company issues warrants to buy 5,407,500 shares with the common stock. The combined price is $6.14. The total, including the pre-funded warrants, is $75,000,093. Each warrant has an exercise price of $7.25 per share. It becomes exercisable on the date of issuance and expires on the fifth anniversary of that date. The offering also includes pre-funded warrants for up to 1,400,000 shares, for buyers who choose them instead of shares. Each is priced at $6.139995 with the same half-warrant, and has an exercise price of $0.000005 per share. Counting the pre-funded warrants, the warrants offered cover up to 6,107,500 shares. The underwriting discount is $0.3684 per share, or $4,500,006 in total. Proceeds to the company before expenses are $70,500,087, and that figure does not include money from any later exercise of the warrants. The last reported sale price on November 10, 2025 was $6.07. ## Who is involved Guggenheim Securities, LLC is the sole underwriter. The underwriting agreement, dated November 10, 2025, obliges it to buy the entire number of shares, pre-funded warrants and warrants offered, subject to conditions. The company agreed to indemnify the underwriter and certain of its affiliates. The filing notes that the underwriter and its affiliates may hold investments in the company or have lending relationships with it. Latham & Watkins LLP passed on legal matters for the company. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., of Boston, passed on legal matters for the underwriter. Deloitte & Touche LLP audited the company's financial statements for the year ended December 31, 2024. The underwriter expected to deliver the securities on or about November 12, 2025. ## Dilution and the balance sheet The company's net tangible book value was about $15.6 million, or $1.29 a share, on 12,082,665 shares outstanding at September 30, 2025. As adjusted for this offering, it would be $85.6 million, or $3.74 a share. The company expects 22,897,665 shares of common stock to be outstanding after the offering, a figure that leaves out shares issuable on the warrants and pre-funded warrants. The supplement does not give a cash balance. Its dilution figures are as of September 30, 2025. The risk factors say buyers "will experience immediate and substantial dilution" in the net tangible book value of the shares they purchase. They add that the company may issue more equity or convertible debt securities later, which could dilute holders again. The company intends to use the net proceeds to fund ongoing and planned research and development, along with working capital and other general corporate purposes. ## The programs behind the raise The company describes itself as a clinical stage gene editing company developing in vivo therapies for genetic and infectious diseases on its ARCUS genome editing platform. Its lead program, PBGENE-HBV, is under investigation in a first-in-human trial designed as a potentially curative treatment for chronic Hepatitis B infection. The trial, called ELIMINATE-B, tests PBGENE-HBV at multiple ascending dose levels, with three dose administrations per level. The trial is recruiting patients in the United States, Moldova, Hong Kong, New Zealand and the United Kingdom. The supplement reports no clinical results from it, so the safety and effect of the drug in patients are not yet shown in this filing. The annual report's forward-looking statements list the company's ability to become profitable, its ability to procure sufficient funding to advance its programs, and risks associated with raising additional capital. They also cite its limited operating history, its dependence on ARCUS, and the risk that other genome-editing technologies may offer significant advantages. They name requirements under its current debt instruments as a further risk. ## What comes next The supplement gives no timetable for ELIMINATE-B data. Any future equity or convertible debt would add to the 22,897,665 shares expected after this deal. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story DTIL Precision BioSciences, Inc. NASDAQ ยท United States Open the starter desk ## More in Financings Financings ### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) Oct 29, 2026 Financings ### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Oct 29, 2026 Financings ### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) Oct 29, 2026 --- Source page: https://aibio.space/news/precision-biosciences-prices-75-000-093-stock-warrant-offering/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Precision BioSciences prices $75,000,093 stock", 2025-11-12, https://aibio.space/news/precision-biosciences-prices-75-000-093-stock-warrant-offering/